ImmunityBio reports preliminary Q1 net product revenue $44.2M

Consensus $43.17M. ANKTIVA is now approved or authorized across five regulatory jurisdictions, representing approximately 34 countries. Additionally, the pivotal BCG-naive CIS trial is fully enrolled, with the IDMC confirming no additional enrollment is required. A supplemental BLA submission is on track for 2026. The Company ended the quarter with an estimated $380.9 million in cash, cash equivalents and marketable securities as of March 31, 2026. “ANKTIVA’s continued momentum reflects growing physician adoption and disciplined commercial execution,” said Richard Adcock, President and CEO of ImmunityBio (IBRX). “Following strong growth in 2025, we are focused on scaling in the U.S. and expanding across an increasing number of global markets.”